Drug intelligence / Profile preview

CHACAR-NK-201

Development stage: Unknown
Lead developer: CHA
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies

Overview

CHACAR-NK-201 is an investigational **allogeneic CAR-NK cell therapy** being developed by CHA for **FR-alpha-overexpressing solid tumors**. The product consists of donor-derived natural killer cells engineered with a chimeric antigen receptor directed against **folate receptor alpha**, with the intended mechanism of selectively recognizing FR-alpha-expressing tumor cells and inducing NK cell-mediated cytotoxic killing. Based on the company pipeline information provided, CHACAR-NK-201 is positioned as an off-the-shelf solid tumor immunotherapy program and is listed in **Phase 1/2** development.

Other names: FR-alpha allogeneic CAR-NK cell therapy

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on CHACAR-NK-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHACAR-NK-201.

Explore the full profile